HomeCONGRESSInternational Congresses

International Congresses

View Category
Day 2

OSLER: Evolocumab reduces cardiovascular events compared with standard statin therapy

The aim of this study was to evaluate the safety and efficacy of long-term Evolocumab, an inhibitor...
solaci -
Learn More
Day 2

ODYSSEY LONG TERM: alirocumab reduces LDL in patients with maximum tolerated doses of statins

The aim of this study was to evaluate treatment with alirocumab a monoclonal antibody against PCSK9 receptor,...
solaci -
Learn More
Day 2

NOTION: TAVR in low-risk patients

The aim of this study was to compare the results of transcatheter aortic valve replacement (TAVR) versus...
solaci -
Learn More
Day 2

EMBRACE STEMI: Bendavia a new drug to prevent mitochondrial dysfunction in AMI.

The purpose of this phase 2 study was to test the safety and efficacy of new drug...
solaci -
Learn More
Day 2

CSPPT: folic acid for primary prevention of stroke

The aim of this study was to evaluate the effectiveness of supplementation with folic acid in primary...
solaci -
Learn More
Day 3

After 80: The octogenarian patients with acute coronary syndrome benefit from an aggressive strategy

This work published simultaneously in The New England Journal of Medicine showed that patients over eighty years...
solaci -
Learn More
Day 3

Mitral valve repair in moderate ischemic mitral regurgitation

Article Up to 50% of acute myocardial infarctions are associated to mitral regurgitation of some degree and 10%...
solaci -
Learn More
Day 3

INHERIT: Losartan in hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy is the most common hereditary cardiac pathology (1/1500) and is associated to heart failure, angina,...
solaci -
Learn More